BioArctic

BioArctic FCF per Share

The Free Cash Flow per Share of BioArctic (BIOA B.ST) as of Sep 26, 2026 is 16.09 SEK. In the previous year, Free Cash Flow per Share was -3.88 SEK — a change of -514.75% (higher).

FCF per Share

16.09SEK

YoY

-514.75%

Last updated:

Free Cash Flow per Share of BioArctic is 2026 16.09 SEK. Free Cash Flow per Share of BioArctic was 2025 -3.88 SEK. It decreases by -514.75% higher compared to the previous year.

The BioArctic FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-2.29 SEK
Jan 1, 2019
3.68 SEK
Jan 1, 2020
-1.19 SEK
Jan 1, 2021
-1.35 SEK
Jan 1, 2022
-0.50 SEK
Jan 1, 2023
3.42 SEK
Jan 1, 2024
-3.88 SEK
Jan 1, 2025
16.09 SEK
The BioArctic FCF per Share history
YEARFCF per ShareYoY
16.09SEK-514.75%
-3.88SEK-213.37%
3.42SEK-779.36%
-0.50SEK-62.57%
-1.35SEK+13.08%
-1.19SEK-132.36%
3.68SEK-260.51%
-2.29SEK+45.41%
-1.58SEK-120.65%
7.63SEK-3,716.75%
-0.21SEK—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Free Cash Flow per Share of BioArctic is 16.09 SEK in 2026.

Free Cash Flow per Share of BioArctic changed from -3.88 SEK to 16.09 SEK, representing a -514.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share BioArctic since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

Cash Flow — BioArctic

All Key Metrics — BioArctic